世界各区域病毒性丙型肝炎流行病学指标分析结果,作为改善患者药物供应活动的一部分

Q3 Pharmacology, Toxicology and Pharmaceutics
A. Nozdrina, A. Volkova, Alina Cherkashyna, O. Ovakimian
{"title":"世界各区域病毒性丙型肝炎流行病学指标分析结果,作为改善患者药物供应活动的一部分","authors":"A. Nozdrina, A. Volkova, Alina Cherkashyna, O. Ovakimian","doi":"10.15587/2519-4852.2022.255858","DOIUrl":null,"url":null,"abstract":"Viral hepatitis affects hundreds of millions of people worldwide, the most dangerous of which are hepatitis B and C.\nThe aim of our study was to study the prevalence and incidence of HC in the world and in Ukraine, as well as approaches in pharmacotherapy of HC to further identify effective measures to eliminate HC and improve pharmaceutical supply to patients in HC in Ukraine. The materials of the study were WHO statistical reports, national country reports, national recommendations for pharmacotherapy, the analysis of which was carried out by methods of generalization of information, analytical, comparative method.\nResults of the research. According to the WHO segmentation, the most frequent cases of HC are found in the populations of the Nordic-Mediterranean region (15 million cases) and the European region (12 million cases). Four countries in the world account for more than 40 % of all people infected with HC, two of which are in the Nordic-Mediterranean region (Pakistan – 7.2 and Egypt – 5.6 million people, respectively). The incidence of HC in Western Europe is up to 0.5 %, while in Northern Europe it is up to 3.3 %. Currently, the highest number of first-time HC infections in 2019 was registered among the populations of Ireland, the United Kingdom and Finland. The lowest incidence rates were found in Romania, Italy and Greece. It has been established that males aged 20–45 years prevail among those infected with HC.\nIt was found that the prevalence of HC in Ukraine in 2015 was 3 %, according to 2020 – 5 %, with the annual number of newly recorded cases of HC increases by at least 7 %. According to the gender distribution, the ratio is on average 1.3 patients among men to 1 patient among women.\nAn analysis of international guidelines for the pharmacotherapy of HC has shown that their latest revisions contain new direct-acting antiviral drugs, namely combinations of drugs such as glecaprevir / pibrentasvir and sofosbuvir / velpatasvir. The standard of HC treatment in Ukraine, approved in January 2021, is more in line with the recommendations of the WHO (2018), AASLD (2019) and EASL (2020) than the 2016 treatment protocol.\nConclusions. The annual rate of HC infection in the world remains very high and is estimated at 1.5 million people. Regular revision and updating of standards of HC treatment with the latest direct-acting antiviral drugs, annual increase in the number of people in the world and in Ukraine who receive timely diagnosis of HCV and its full treatment are effective steps to achieve the goal of eliminating viral hepatitis","PeriodicalId":21674,"journal":{"name":"ScienceRise: Pharmaceutical Science","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Results of analysis of epidemological indicators of viral hepatitis c in regions of the world as part of activities to improve pharmaceutical provision for patients\",\"authors\":\"A. Nozdrina, A. Volkova, Alina Cherkashyna, O. Ovakimian\",\"doi\":\"10.15587/2519-4852.2022.255858\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Viral hepatitis affects hundreds of millions of people worldwide, the most dangerous of which are hepatitis B and C.\\nThe aim of our study was to study the prevalence and incidence of HC in the world and in Ukraine, as well as approaches in pharmacotherapy of HC to further identify effective measures to eliminate HC and improve pharmaceutical supply to patients in HC in Ukraine. The materials of the study were WHO statistical reports, national country reports, national recommendations for pharmacotherapy, the analysis of which was carried out by methods of generalization of information, analytical, comparative method.\\nResults of the research. According to the WHO segmentation, the most frequent cases of HC are found in the populations of the Nordic-Mediterranean region (15 million cases) and the European region (12 million cases). Four countries in the world account for more than 40 % of all people infected with HC, two of which are in the Nordic-Mediterranean region (Pakistan – 7.2 and Egypt – 5.6 million people, respectively). The incidence of HC in Western Europe is up to 0.5 %, while in Northern Europe it is up to 3.3 %. Currently, the highest number of first-time HC infections in 2019 was registered among the populations of Ireland, the United Kingdom and Finland. The lowest incidence rates were found in Romania, Italy and Greece. It has been established that males aged 20–45 years prevail among those infected with HC.\\nIt was found that the prevalence of HC in Ukraine in 2015 was 3 %, according to 2020 – 5 %, with the annual number of newly recorded cases of HC increases by at least 7 %. According to the gender distribution, the ratio is on average 1.3 patients among men to 1 patient among women.\\nAn analysis of international guidelines for the pharmacotherapy of HC has shown that their latest revisions contain new direct-acting antiviral drugs, namely combinations of drugs such as glecaprevir / pibrentasvir and sofosbuvir / velpatasvir. The standard of HC treatment in Ukraine, approved in January 2021, is more in line with the recommendations of the WHO (2018), AASLD (2019) and EASL (2020) than the 2016 treatment protocol.\\nConclusions. The annual rate of HC infection in the world remains very high and is estimated at 1.5 million people. Regular revision and updating of standards of HC treatment with the latest direct-acting antiviral drugs, annual increase in the number of people in the world and in Ukraine who receive timely diagnosis of HCV and its full treatment are effective steps to achieve the goal of eliminating viral hepatitis\",\"PeriodicalId\":21674,\"journal\":{\"name\":\"ScienceRise: Pharmaceutical Science\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ScienceRise: Pharmaceutical Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15587/2519-4852.2022.255858\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ScienceRise: Pharmaceutical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15587/2519-4852.2022.255858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1

摘要

病毒性肝炎影响全球数亿人,其中最危险的是乙型肝炎和丙型肝炎。本研究的目的是研究丙型肝炎在世界和乌克兰的患病率和发病率,以及丙型肝炎的药物治疗方法,以进一步确定消除丙型肝炎的有效措施,改善乌克兰丙型肝炎患者的药物供应。本研究的材料为世界卫生组织统计报告、各国报告、各国药物治疗建议,采用资料归纳、分析、比较等方法进行分析。研究结果。根据世卫组织的细分,最常见的HC病例发生在北欧-地中海区域(1500万例)和欧洲区域(1200万例)。世界上四个国家占所有丙型肝炎感染者的40%以上,其中两个在北欧-地中海区域(巴基斯坦- 720万人和埃及- 560万人分别)。在西欧,丙型肝炎的发病率高达0.5%,而在北欧则高达3.3%。目前,2019年首次感染丙型肝炎的人数最多的是爱尔兰、英国和芬兰。罗马尼亚、意大利和希腊的发病率最低。已经确定,在感染丙型肝炎的人中,年龄在20-45岁的男性居多。结果发现,2015年乌克兰丙型肝炎的患病率为3%,根据2020 - 5%,每年新记录的丙型肝炎病例数至少增加7%。按性别分布,男性平均1.3例:女性平均1例。对丙肝药物治疗国际指南的分析表明,其最新修订版包含新的直接作用抗病毒药物,即glecaprevir / pibrentasvir和sofosbuvir / velpatasvir等药物的组合。乌克兰于2021年1月批准的HC治疗标准比2016年的治疗方案更符合WHO(2018)、AASLD(2019)和EASL(2020)的建议。世界上丙型肝炎的年感染率仍然很高,估计为150万人。定期修订和更新丙型肝炎治疗标准,使用最新的直接作用抗病毒药物,每年增加世界和乌克兰及时诊断和全面治疗丙型肝炎的人数,是实现消除病毒性肝炎目标的有效步骤
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Results of analysis of epidemological indicators of viral hepatitis c in regions of the world as part of activities to improve pharmaceutical provision for patients
Viral hepatitis affects hundreds of millions of people worldwide, the most dangerous of which are hepatitis B and C. The aim of our study was to study the prevalence and incidence of HC in the world and in Ukraine, as well as approaches in pharmacotherapy of HC to further identify effective measures to eliminate HC and improve pharmaceutical supply to patients in HC in Ukraine. The materials of the study were WHO statistical reports, national country reports, national recommendations for pharmacotherapy, the analysis of which was carried out by methods of generalization of information, analytical, comparative method. Results of the research. According to the WHO segmentation, the most frequent cases of HC are found in the populations of the Nordic-Mediterranean region (15 million cases) and the European region (12 million cases). Four countries in the world account for more than 40 % of all people infected with HC, two of which are in the Nordic-Mediterranean region (Pakistan – 7.2 and Egypt – 5.6 million people, respectively). The incidence of HC in Western Europe is up to 0.5 %, while in Northern Europe it is up to 3.3 %. Currently, the highest number of first-time HC infections in 2019 was registered among the populations of Ireland, the United Kingdom and Finland. The lowest incidence rates were found in Romania, Italy and Greece. It has been established that males aged 20–45 years prevail among those infected with HC. It was found that the prevalence of HC in Ukraine in 2015 was 3 %, according to 2020 – 5 %, with the annual number of newly recorded cases of HC increases by at least 7 %. According to the gender distribution, the ratio is on average 1.3 patients among men to 1 patient among women. An analysis of international guidelines for the pharmacotherapy of HC has shown that their latest revisions contain new direct-acting antiviral drugs, namely combinations of drugs such as glecaprevir / pibrentasvir and sofosbuvir / velpatasvir. The standard of HC treatment in Ukraine, approved in January 2021, is more in line with the recommendations of the WHO (2018), AASLD (2019) and EASL (2020) than the 2016 treatment protocol. Conclusions. The annual rate of HC infection in the world remains very high and is estimated at 1.5 million people. Regular revision and updating of standards of HC treatment with the latest direct-acting antiviral drugs, annual increase in the number of people in the world and in Ukraine who receive timely diagnosis of HCV and its full treatment are effective steps to achieve the goal of eliminating viral hepatitis
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ScienceRise: Pharmaceutical Science
ScienceRise: Pharmaceutical Science Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.70
自引率
0.00%
发文量
39
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信